Noonan and Noonan-like syndromes are disorders of dysregulation of the rat sarcoma viral oncogene homolog (RAS)-mitogen-activated protein kinase signaling pathway. In Noonan syndrome (NS), four genes of this pathway (PTPN11, SOS1, RAF1, and KRAS) are responsible for roughly 70% of the cases. We analyzed PTPN11 and KRAS genes by bidirectional sequencing in 95 probands with NS and 29 with Noonan-like syndromes, including previously reported patients already screened for PTPN11 gene mutations. In the new patients with NS, 20/46 (43%) showed a PTPN11 gene mutation, two of them novel. In our total cohort, patients with NS and a PTPN11 mutation presented significantly higher prevalence of short stature (p = 0.03) and pulmonary valve stenosis (p = 0.01), and lower prevalence of hypertrophic cardiomyopathy (p = 0.01). Only a single gene alteration, of uncertain role, was found in the KRAS gene in an NS patient also presenting a PTPN11 gene mutation. We further analyzed the influence in clinical variability of three frequent polymorphisms found in the KRAS gene and no statistically significant difference was observed among the frequency of clinical findings regarding the studied polymorphisms.
Get full access to this article
View all access options for this article.
References
1.
AokiY, NiihoriT, KawameHet al.2005. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet, 37:1038-1040.
2.
AokiY, NiihoriT, NarumiYet al.2008. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat, 29:992-1006.
3.
BertolaDR, PereiraAC, AlbanoLMet al.2006. PTPN11 gene analysis in 74 Brazilian patients with Noonan syndrome or Noonan-like phenotype. Genet Test, 10:186-191.
4.
BertolaDR, PereiraAC, BrasilASet al.2007. Further evidence of genetic heterogeneity in Costello syndrome: involvement of the KRAS gene. J Hum Genet, 52:521-526.
5.
BertolaDR, PereiraAC, PassettiFet al.2005. Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient. Am J Med Genet A, 136:242-245.
6.
CartaC, PantaleoniF, BocchinfusoGet al.2006. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet, 79:129-135.
FerreroGB, BaldassarreG, DelmonacoAGet al.2008. Clinical and molecular characterization of 40 patients with Noonan syndrome. Eur J Med Genet, 51:566-572.
GrippKW. 2005. Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet, 137C:72-77.
16.
IonA, TartagliaM, SongXet al.2002. Absence of PTPN11 mutations in 28 cases of cardiofaciocutaneous (CFC) syndrome. Hum Genet, 111:421-427.
17.
KalidasK, ShawAC, CrosbyAHet al.2005. Genetic heterogeneity in LEOPARD syndrome: two families with no mutations in PTPN11. J Hum Genet, 50:21-25.
18.
KavamuraMI, PomponiMG, ZollinoMet al.2003. PTPN11 mutations are not responsible for the Cardiofaciocutaneous (CFC) syndrome. Eur J Hum Genet, 11:64-68.
19.
KerenB, HadchouelA, SabaSet al.2004. PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience. J Med Genet, 41:e117.
20.
KerrB, DelrueMA, SigaudySet al.2006. Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet, 43:401-405.
21.
KoJM, KimJM, KimGH, YooHW. 2008. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet, 53:999-1006.
22.
LeeST, KiCS, LeeHJ. 2007. Mutation analysis of the genes involved in the Ras-mitogen-activated protein kinase (MAPK) pathway in Korean patients with Noonan syndrome. Clin Genet, 72:150-155.
LoFS, LinJL, KuoMTet al.2009. Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature. Eur J Pediatr, 168:919-923.
25.
MarquezineGF, OliveiraCM, PereiraACet al.2008. Metabolic syndrome determinants in an urban population from Brazil: social class and gender-specific interaction. Int J Cardiol, 129:259-265.
26.
MillerSA, DykesDD, PoleskyHF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16:1215.
27.
MusanteL, KehlHG, MajewskiFet al.2003. Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome. Eur J Hum Genet, 11:201-206.
28.
NavaC, HannaN, MichotCet al.2007. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet, 44:763-771.
29.
NiihoriT, AokiY, NarumiYet al.2006. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet, 38:294-296.
30.
NoonanJA. 1994. Noonan syndrome. An update and review for the primary pediatrician. Clin Pediatr (Phila), 33:548-555.
31.
NystromAM, EkvallS, BerglundEet al.2008. Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders. J Med Genet, 45:500-506.
32.
PanditB, SarkozyA, PennacchioLAet al.2007. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet, 39:1007-1012.
33.
PereiraAC, FlorianoMS, MotaGFet al.2003a. Beta2 adrenoceptor functional gene variants, obesity, and blood pressure level interactions in the general population. Hypertension, 42:685-692.
34.
PereiraAC, MotaGF, CunhaRSet al.2003b. Angiotensinogen 235T allele “dosage” is associated with blood pressure phenotypes. Hypertension, 41:25-30.
RazzaqueMA, NishizawaT, KomoikeYet al.2007. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet, 39:1013-1017.
37.
Rodriguez-VicianaP, TetsuO, TidymanWEet al.2006. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science, 311:1287-1290.
38.
SarkozyA, CartaC, MorettiSet al.2009. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat, 30:695-702.
SeishimaM, MizutaniY, ShibuyaYet al.2007. Malignant melanoma in a woman with LEOPARD syndrome: identification of a germline PTPN11 mutation and a somatic BRAF mutation. Br J Dermatol, 157:1297-1299.
42.
SharlandM, BurchM, McKennaWM, PatonMA. 1992. A clinical study of Noonan syndrome. Arch Dis Child, 67:178-183.
43.
SovikO, SchubbertS, HougeGet al.2007. De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet, 44:e84.
44.
SunyaevS, RamenskyV, KochIet al.2001. Prediction of deleterious human alleles. Hum Mol Genet, 10:591-597.
45.
TartagliaM, KalidasK, ShawAet al.2002. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet, 70:1555-1563.
46.
TartagliaM, MehlerEL, GoldbergRet al.2001. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet, 29:465-468.
47.
TartagliaM, PennacchioLA, ZhaoCet al.2007. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet, 39:75-79.
48.
ThielC, WilkenM, ZenkerMet al.2009. Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome. Am J Med Genet A, 149A:1263-1267.
49.
van der BurgtI, BerendsE, LommenEet al.1994. Clinical and molecular studies in a large Dutch family with Noonan syndrome. Am J Med Genet, 53:187-191.
ZenkerM, LehmannK, SchulzALet al.2007. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet, 44:131-135.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
